WSHU sits down with CT Mirror’s Katy Golvala to discuss her story about the debate over Medicaid coverage of weight loss ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

Tom Nolan reviews this week’s research Is it time to treat male partners of women with bacterial vaginosis? A trial in the New England Journal of Medicine recruited women with confirmed bacterial ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Daily habits like eating oranges, staying active, and managing medications may help protect your mental health and prevent ...

Studies show that eating oranges daily, regular exercise, and certain medications can lower depression risk by up to 40%, ...

An orange a day, regular moderate-to-vigorous exercise, and GLP-1 drugs for diabetes treatment have all been linked to a ...